Who owns Adaptimmune Therapeutics?
- Ticker: ADAPY
- CUSIP Number: 00653a107
Tip: Access positions for across all investors
Analyze quarterly positions in Adaptimmune Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Adaptimmune Therapeutics stock
Who bought or sold Adaptimmune Therapeutics this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Empirical Finance | 800k | $21k | 0% | Dec 2025 |
|
| XTX Topco | 354k | $9.2k | 245% | Dec 2025 |
|
| Simplex Trading | 19k | $483.860000 | 50% | Dec 2025 |
|
| Rhumbline Advisers | 3.7k | $72.121700 | 0% | Mar 2026 |
|
| Barclays | 2.5k | $66.085200 | 0% | Dec 2025 |
|
Who sold out of Adaptimmune Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Renaissance Technologies | Sep 2025 | 4.1M | $527k |
| Rathbones Brothers | Dec 2025 | 433k | $11k |
| FMR | Sep 2025 | 340k | $44k |
| Susquehanna International | Sep 2025 | 308k | $40k |
| Captrust Financial Advisors | Sep 2025 | 69k | $8.9k |
| Northern Trust | Sep 2025 | 49k | $6.3k |
| Raymond James Financial | Sep 2025 | 25k | $3.3k |
| Josh Arnold Investment Consultant | Dec 2025 | 20k | $38k |
| Prosperity Wealth Management | Sep 2025 | 19k | $2.5k |
| Acadian Asset Management | Dec 2025 | 17k | $0 |
| Traynor Capital Management | Sep 2025 | 15k | $2.0k |
| X-Square Capital | Dec 2025 | 11k | $0 |